AGI and Epitomics, Inc. announce a diagnostic and clinical biomarker collaboration to create superior IHC reagents. The recently announced collaboration will combine Epitomics’ proprietary rabbit monoclonal antibody production with AGI’s IHC screening expertise and clinical diagnostic assessment to develop superior immunohistochemistry reagents. Monoclonals will be screened and developed for their potential as biomarkers for disease classification supplementing AGI’s Panels of Diversity. Many of these IHC-optimized antibodies will also be available as a research reagent product line, termed AGI-Select, from the Epitomics catalog. View news announcement or read more details.